Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELA026 in Relapsed/Refractory T/NK Cell Malignancies
NCT07465835Phase 1Recruiting
- Sponsor
- Electra Therapeutics
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ELA026 in T-cell lymphoma (PTCL) and Natural killer cell malignancy (NKCM) (3 arms), sponsored by Electra Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 35 days and Treatment-Emergent Adverse Events at 28 weeks. Started Feb 2026; status: recruiting.
02
Drugs
ELA026
03
Conditions
T-cell lymphoma (PTCL)Natural killer cell malignancy (NKCM)
Beyond the preview
Go deeper on NCT07465835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465835.